Liposome-based drug carrier for immune anticancer therapy and method for producing same
AssigneeKonkuk University Industrial Cooperation Corp.
InventorDong-eun KIM
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a liposome-based drug carrier for immune anticancer therapy, which includes a liposome; an aptamer which is a target-specific ligand for cancer cells conjugated on the surface of the liposome; and an immunogenic chemo-anticancer agent and siRNA, an immunosuppressive protein inhibitor, which are co-loaded to the liposome. Accordingly, it is possible to induce a continuous tumor-specific anticancer immune response in cancer patients having a low response rate to a standalone immunogenic anticancer agent therapy, and to reduce side effects due to non-specific drug delivery, thereby increasing the effects of immune anticancer therapy.
Claims15
A liposome-based drug carrier for immune anticancer therapy, comprising:
- a liposome;
- an aptamer which is a target-specific ligand for cancer cells conjugated on the surface of the liposome;
- and
- an immunogenic chemo-anticancer agent and siRNA, an immunosuppressive protein expression inhibitor, which are co-loaded to the liposome.
A method for preparing a liposome-based drug carrier for immune anticancer therapy, comprising:
- (a) a step of preparing a cationic liposome comprising siRNA, which is an immunosuppressive protein inhibitor, and a micelle;
- (b) a step of forming a liposome particle comprising the immunosuppressive protein inhibitor siRNA, with a predetermined size, by mixing and sonicating the cationic liposome and the micelle, and then extruding the same;
- (c) a step of preparing an aptamer-conjugated micelle by reacting an aptamer which is a cancer cell target-specific ligand with the micelle;
- and
- (d) a step of mixing the aptamer-conjugated micelle, the liposome particle containing the immunosuppressive protein inhibitor siRNA, and an immunogenic chemo-anticancer agent.
Dependencies are inferred from the claim text.